Are some orphan drugs for rare diseases too expensive? A study of purchase versus compounding costs

被引：8

作者：

Simoens S. ^{[1
]}

Cassiman D. ^{[2
]}

Picavet E. ^{[1
]}

Dooms M. ^{[3
]}

机构：

[1] Research Centre for Pharmaceutical Care and Pharmaco-economics, Katholieke Universiteit Leuven, 3000 Leuven, Onderwijs en Navorsing 2

[2] Department of Hepatology, University Hospital Leuven, Leuven

[3] Hospital Pharmacy, University Hospital Leuven, Leuven

来源：

Drugs & Therapy Perspectives | 2011年 / 27卷 / 10期

关键词：

Orphan Drug; Healthcare Payer; Orphan Designation; Belgian Hospital; Hospital Price;

D O I：

10.2165/11601640-000000000-00000

中图分类号：

学科分类号：

摘要：

Hospital purchase prices substantially exceed compounding production costs in Belgium for selected orphan drugs that had low costs of research and development and market access procedures. As a result, healthcare payers seem to be paying too much for these orphan drugs and there are arguments for price reductions. Pharmacies can consider compounding, rather than purchasing, these orphan drugs. © 2011 Adis Data Information BV. All rights reserved.

引用

页码：24 / 26

页数：2

共 50 条

[21] The challenges of pharmacoepidemiology of orphan drugs in rare diseases
Lapeyre-Mestre, Maryse
THERAPIE, 2020, 75 (02): : 215 - 220
[22] Orphan drugs und seltene EpilepsienOrphan drugs and rare diseases
Andreas Schulze-Bonhage
Ulrich Stephani
Zeitschrift für Epileptologie, 2019, 32 (4): : 263 - 263
[23] Neglected tropical diseases in Europe: rare diseases and orphan drugs?
Calleri, Guido
Angheben, Andrea
Albonico, Marco
INFECTION, 2019, 47 (01) : 3 - 5
[24] Negotiating Medical Insurance Drug Prices: The Role in Reducing Costs of Orphan Drugs for Rare Diseases
Lu, Jinmiao
Ying, Xiaohua
Li, Zhiping
INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT, 2023, 12 (01)
[25] Neglected tropical diseases in Europe: rare diseases and orphan drugs?
Guido Calleri
Andrea Angheben
Marco Albonico
Infection, 2019, 47 : 3 - 5
[26] Rare diseases, orphan drugs and their regulation: questions and misconceptions
Tambuyzer, Erik
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (12) : 921 - 929
[27] Clinical experience with orphan drugs for rare metabolic diseases
Caso-Gonzalez, Alicia
Nunez-Rodriguez, Jesica
Nebot-Villacampa, Maria-Jose
Gonzalez-Perez, Yared
Marin-Gorricho, Raquel
Leralta-Gonzalez, Claudia
Obaldia-Alana, Carmen
ANALES DE PEDIATRIA, 2022, 96 (01): : 8 - 16
[28] The use of patient registries for orphan drugs and rare diseases
Clarke, Joe T. R.
Hernberg-Stahl, Elizabeth
EJHP PRACTICE, 2010, 16 (04): : 30 - 31
[29] OF RARE DISEASES AND ORPHAN DRUGS: A REVIEW OF CURRENT NEUROSCIENCE
Polanco-Carrasco, Roberto
PSIENCIA-REVISTA LATINOAMERICANA DE CIENCIA PSICOLOGICA, 2010, 2 (01): : 8 - 14
[30] The availability and affordability of orphan drugs for rare diseases in China
Shiwei Gong
Yingxiao Wang
Xiaoyun Pan
Liang Zhang
Rui Huang
Xin Chen
Juanjuan Hu
Yi Xu
Si Jin
Orphanet Journal of Rare Diseases, 11

← 1 2 3 4 5 →